Wilson R H, Houston R F, Moorehead R J
Northern Ireland Centre for Clinical Oncology, Belvoir Park Hospital, Belfast.
Ulster Med J. 1994 Apr;63(1):44-51.
Survival from colorectal cancer has not improved over the last four decades despite advances in surgery and anaesthesia. The answer to the question whether adjuvant chemotherapy and radiotherapy will improve survival from the disease can only come from randomised, controlled trails. In the future, immunotherapy and gene therapy may be of benefit but these are still many years from the clinical arena. We believe that current evidence suggests that patients with Dukes B and C colorectal cancer should be entered into trials of adjuvant therapy. This evidence is reviewed below among with estimates of the impact that adjuvant therapy would have on the outcome from this disease in Northern Ireland.
尽管在外科手术和麻醉方面取得了进展,但在过去的四十年里,结直肠癌患者的生存率并未得到提高。辅助化疗和放疗能否提高该疾病的生存率这一问题的答案,只能来自随机对照试验。未来,免疫疗法和基因疗法可能会带来益处,但距离进入临床应用仍有很多年。我们认为,目前的证据表明,患有杜克B期和C期结直肠癌的患者应参与辅助治疗试验。以下将对这一证据进行综述,并评估辅助治疗对北爱尔兰该疾病治疗结果的影响。